BioSyent Inc.
TSX VENTURE : RX

BioSyent Inc.

May 13, 2008 19:58 ET

BioSyent Pharma Establishes Hospital Products Division-Secures First Supply Contract and Orders for New Product

MISSISSAUGA, ONTARIO--(Marketwire - May 13, 2008) - BioSyent Inc. ("BioSyent")(TSX VENTURE:RX) announces that it has established a new Hospital Products Division focused on licensing or acquiring pharmaceutical products used primiarily in a hospital setting, and marketing those products across Canada.

The Hospital Products Division of BioSyent Pharma Inc. has licensed Ciprofloxacin Injection, an anti-bacterial agent, for the Canadian market. Ciprofloxacin Injection is a generic equivalent to CIPRO I.V. Minibags 2mg/ml from Bayer Inc. on which the remaining patents expired recently.

BioSyent Pharma has launched Ciprofloxacin Injection to the Canadian market and has secured its first supply contract and order for the product.

BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. These pharmaceuticals will compete in both the branded and generic market segments and will not require further product development investment other than regulatory costs.

BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.

Contact Information